Results 21 to 30 of about 1,191,068 (306)

High Carbohydrate Antigen 19-9 Levels Indicate Poor Prognosis of Upper Tract Urothelial Carcinoma

Frontiers in Oncology, 2022
Upper tract urothelial carcinoma (UTUC) occurs in urothelial cells from the kidney and the ureters. Carbohydrate antigen 19-9 (CA 19-9) is a tumor marker for pancreatic and gastrointestinal cancers, and its high levels are associated with poor prognosis ...
Seung-hwan Jeong, Jang Hee Han, Chang Wook Jeong, Chang Wook Jeong, Hyeon Hoe Kim, Hyeon Hoe Kim, Cheol Kwak, Cheol Kwak, Hyeong Dong Yuk, Hyeong Dong Yuk, Ja Hyeon Ku, Ja Hyeon Ku   +11 more
doaj   +1 more source

Increasing the Sensitivity of ELISA using Multiplexed Electrokinetic Concentrator [PDF]

, 2009
We developed a novel method to increase the sensitivity of standard enzyme-linked immunosorbent assay (ELISA) using a multiplexed electrokinetic concentration chip.
Catalona W., Duffy D. C., Gorris H., Humble P. H., Kim S. J., Lee J., Lee J. H., Lee J. H., Nam J.-M., Ohashi T., Probstein R. F., Sato K., Sato K., Schweitzer B., Seong G. H. S., Steinberg W., Wang Y.-C., Wang Y.-C., Wild D., Wu G., Zheng G., Zhou M.   +21 more
core   +1 more source

CA 19-9 like epitope(s) on carcinoembryonic antigen molecules.

RADIOISOTOPES, 1989
CA 19-9 epitope(s) on carcinoembryonic antigen (CEA) was studied by a method designated the hybrid immunoradiometric-assay (hybrid IRMA) using solid phase CEA antibody to capture the CEA molecule and radio-labeled NS 19-9 antibody as a detector. The radioactivities of the hybrid IRMA of respective sera with certain cancers differed from that of normal ...
A, Nagata, T, Komoda
openaire   +3 more sources

Unclassified autoimmune pancreatitis mimicking pancreatic cancer [PDF]

, 2019
A 24-year-old black male presented with a 1-week obstructive jaundice and intermittent abdominal pain, with no significant weight loss and an unsuspicious abdominal exam.
Alves, A, Marinho, R, Nunes, V, Pignatelli, N   +3 more
core   +1 more source

Predictors of malignancy in pancreatic head mass: a prospective study

The Pan African Medical Journal, 2011
INTRODUCTION: The objective of the study was to identify the predictive factors for malignancy in pancreatic head mass as a primary outcome and assess the value of CA 19-9 as a diagnostic tool for malignancy as a secondary outcome.
Arjun Sivaraman, Ashok Muthukrishnan, Nagendra Boopathy Senguttvan, Suraj Anil Suchak, Umashankkar Kannan   +4 more
doaj   +1 more source

The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of Pancreas [PDF]

Journal of Clinical and Diagnostic Research, 2016
Introduction: Carbohydrate antigen 19-9 (CA 19-9) is a tumour associated antigen. Blood levels may be elevated in benign as well as malignant conditions. Its sensitivity (70-90%) and specificity (68-91%) are inadequate for accurate diagnosis.
Jayabal Pandiaraja, Subramanian Viswanathan, Thomas Babu Antomy, Sathyamoorthy Thirumuruganand, Dhandapani Subramanian Kumaresan   +4 more
doaj   +1 more source

Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses [PDF]

, 2013
<p>Background: Activation of blood coagulation and fibrinolysis may be associated with increased risk of coronary heart disease. We aimed to assess associations of circulating tissue plasminogen activator (t-PA) antigen, D-dimer and von Willebrand ...
Aspelund, T., Di Angelantonio, E., Eiriksdottir, G., Gudnason, V., Lowe, G., Rumley, A., Thompson, A., Willeit, P.   +7 more
core   +15 more sources

Prognostic significance of carbohydrate antigen 19-9 (CA19-9) change during immediate postoperative periods in patients with stage I–III colorectal cancer [PDF]

Annals of Coloproctology
Purpose Although carbohydrate antigen 19-9 (CA19-9) may exhibit low sensitivity in tumor screening, its prognostic significance has been highlighted. This study assessed the significance of preoperative CA19-9 and early postoperative CA19-9 levels in ...
Wooram Choi, Yongjung Park, Jeonghyun Kang   +2 more
doaj   +1 more source

Tumor markers in breast cancer - European Group on Tumor Markers recommendations [PDF]

, 2005
Recommendations are presented for the routine clinical use of serum and tissue-based markers in the diagnosis and management of patients with breast cancer.
Abraha RS, Andreasen PA, Arie van Dalen, ASCO Expert Panel, Barak V, Barnes DM, Baselga J, Bast RC, Benraad TH, Bieglmayer C, Blamey RW, Bonadonna G, Chan DW, Chebil G, Chu KC, Colditz G, Conneely OM, De Koning H, Devine PL, Dixon AR, Dnistrian AM, Dnistrian AM, Duffy MJ, Duffy MJ, Duffy MJ, Duffy MJ, Duffy MJ, Early Breast Cancer Trialist's, Early Breast Cancer Trialists Collaborative Group, Early Breast Cancer Trialists Collaborative Group, Easton DF, Ebeling FC, Ebeling FG, Eifel P, Einarsson R, Ekbom A, Elledge RM, Fisher B, Fitzgibbons PL, Gion M, Gion M, Guadagni F, Gyö, Harries M, Harvey JM, Helena Goike, Holli K, Holli K, Iwase H, Jager W, Jensen EV, Kamel EM, Konecny G, Kurebayashi J, Lamerz R, Leake R, Leers M, Leers MP, Leers MP, Legha SS, Leyland-Jones B, Look MP, Loomer L, Loprinzi CL, Madigan MP, Marius Nap, Massimo Gion, McCarty, McLaughlin R, Merimsky O, Michael J. Duffy, Mohsin SK, Molina R, Molina R, Molina R, Molina R, Molina R, Molina R, Molina R, Morrow M, Nakata B, Newcomb P, Nicolini A, Nicolini A, Nicolini A, O'Hanlon DM, Paik S, Palazzo S, Parker SL, Parkin DN, Pecking AP, Pertschuk LP, Pertschuk LP, Petra Stieber, Piccart MJ, Price MR, Rafael Molina, Robertson JFR, Robertson JFR, Rogers CE, Roland Einarsson, Rolf Lamerz, Romer M, Rosselli del Turco M, Safi F, Schapira DV, Schapira DV, Sjostrom J, Slamon D, Soletormos G, Soletormos G, Soletormos G, Soletormos G, Stieber P, Sturgeon CM, Sweep CGJ, Tabar L, The GIVIO, The GIVIO, Theriault RL, Thorpe SM, Tomlinson IP, Tondini C, Van Dalen A, Van Dalen A, van Dalen A, van Dalen A, Van Dalen A, van Dalen A, Veronesi U, Vivian Barak, Vizcarra E, Vyzula R, Weihua Z, Williams MR, Yamauchi H, Zucchelli GC   +136 more
core   +1 more source

Limits of serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 as the diagnosis of gallbladder cancer

Annals of Hepato-Biliary-Pancreatic Surgery, 2021
Introduction Because the clinical symptoms of gallbladder (GB) cancers are lacking or vague, objective tools for diagnosing GB cancer were necessary. Although serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 were widely utilized for the diagnosis of GB cancer, few studies existed about the diagnostic performance of these ...
Jae Seung KANG, Yoo Jin CHOI, Yoonhyeong BYUN, Youngmin HAN, Jung Min LEE, Hee Ju SOHN, Hongbeom KIM, Wooil KWON, Jin-Young JANG   +8 more
openaire   +2 more sources